# LifeArc Ventures

> LifeArc Ventures is a VC fund in London backing Health Care and Biotechnology. See 18 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 18
- Last investment: Jun 2026
- Lead investor: 44%
- Last updated: Aug 2026
- Website: https://www.lifearc.org/funding/venture-investment

LifeArc Ventures is a VC fund in London focused on Health Care and Biotechnology. LifeArc Ventures a self-funding medical research charity that invests in Seed and Series-A stage Biotech and Healthtech companies.

## Contacts

5 contacts available for LifeArc Ventures. Shizune tracks 1 team members at LifeArc Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/lifearc-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 22% |
| Biotechnology | 4 | 22% |
| Therapeutics | 3 | 17% |
| Life Science | 2 | 11% |
| Pharmaceutical | 2 | 11% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 22% |
| Series B | 3 | 17% |
| Seed | 2 | 11% |
| Funding Round | 1 | 6% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 4 | 22% |
| United States | 2 | 11% |
| Sweden | 1 | 6% |
| Germany | 1 | 6% |
| Switzerland | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Imran Hamid | Senior Investment Principal | 5 | https://shizune.co/investors/profile/imran-hamid-2bea |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| RQ Bio | RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza with the goal of providing immediate, powerful, and long-lasting protection against severe viral disease in immunocompromised and high-risk subjects. The company's mission is to deliver "instant immunity" through passiveimmunization, helping protect vulnerable populations such as the elderly, newborns, and immunocompromised patients from severe infectious diseases. The company specializes in the discovery and development of broad-spectrum antiviral antibodies that are engineered to remain effective even as viruses evolve. Its scientific approach combines virology, antibody engineering, computational biology, and immune-directed discovery techniques to identify potent antibodies that target conserved regions of viral proteins, reducing the risk of resistance caused by viral mutations.RQ Bio's lead programs focus on infectious diseases such as influenza, COVID-19, respiratory syncytial virus (RSV), and cytomegalovirus (CMV). The company is currently developing long-acting monoclonal antibodies designed to provide once-yearly protection against seasonal influenza, particularly for individuals at high risk of severe disease. | $112.5M | Series A | Jun 24, 2026 | https://www.rqbiotechnology.com/ |
| Cytospire Therapeutics | Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers. | $82.6M | Series A | May 05, 2026 | https://www.cytospire.com/ |
| Exciva | exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using suchcompositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses. | $62.2M | Series B | Jan 20, 2026 | http://www.exciva.com/ |
| Affect | Affect Therapeutics is using mobile technology to revolutionize stimulant addiction recovery. | $26M | Series B | Sep 23, 2025 | https://www.affecttherapeutics.com/ |
| GlycoEra | GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics. | $130M | Series B | May 27, 2025 | https://glycoera.com |
| Tribune Therapeutics | Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. | $24.7M | Series A | Mar 26, 2025 | https://tribunetx.com/ |
| Hillstar Bio | Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases. | $67M | Series A | Mar 25, 2025 | https://hillstarbio.com/ |
| Maxion Therapeutics | Maxion Therapeutics helps in learning transformative therapies. It uses this technology to deliver long-acting, safe, and effective medications against previously inaccessible targets. | $75.3M | Series A | Mar 17, 2025 | https://www.maxiontherapeutics.com/ |
| Fluid Biomed | Fluid Biotech is a Calgary based company that aims to develop the next generation of stents to improve patient well-being and realise better health and quality of life through innovation. | $27M | Series A | Dec 16, 2024 | https://www.fluidbiotech.com |
| Ikarovec | Ikarovec is developing novel gene therapies to treat major ophthalmic indications. | $10.3M | Seed | Oct 23, 2024 |  |

10 of 18 investments shown.

## Co-investors
- [Artis Ventures](https://shizune.co/investors/profile/artis) — VC Fund, 3 deals together
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund, 3 deals together
- [Modi Ventures](https://shizune.co/investors/profile/modi-ventures) — VC Fund, 3 deals together
- [Monograph Capital](https://shizune.co/investors/profile/monograph-capital) — VC Fund, 3 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 3 deals together
- [4BIO Capital](https://shizune.co/investors/profile/4bio-capital-partners) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Chalmers Ventures AB](https://shizune.co/investors/profile/chalmers-ventures) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Sweden](https://shizune.co/investors/biotechnology-investors-sweden)
- [Biotechnology VC Funds in Sweden](https://shizune.co/investors/biotechnology-vc-funds-sweden)
- [Biotech Investors in Sweden](https://shizune.co/investors/biotech-investors-sweden)
- [Biotech VC Funds in Sweden](https://shizune.co/investors/biotech-vc-funds-sweden)

## FAQ

### What does LifeArc Ventures invest in?

LifeArc Ventures invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact LifeArc Ventures?

Public channels for LifeArc Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at LifeArc Ventures?

The team at LifeArc Ventures includes Imran Hamid (Senior Investment Principal). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co